Monitor for any subsequent filings that might contain financial results or strategic announcements. The recent insider selling warrants attention but is not directly related to this proxy filing.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $22.48entry
- T+1 · 7mo ago −2.47%α −1.98% · $21.92
- T+5 · 7mo ago +1.09%α +0.69% · $22.72
- T+20 · 6mo ago −2.20%α −7.16% · $21.98
- T+60 · 4mo ago +24.40%α +19.63% · $27.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bicara Therapeutics Inc. filed a definitive proxy statement for a shareholder vote on director elections, executive compensation, and other corporate governance matters. The filing is routine and does not contain any material financial or strategic changes.
Key Financial Metrics
Key Facts
- Filing is a DEFA14A, which is a definitive proxy statement for a shareholder meeting
- No activist campaign or contested vote is indicated
- Filing contains standard corporate governance items: director elections, executive compensation, auditor ratification
- No financial figures or strategic changes are disclosed in the filing
- Market data shows recent insider selling of $750K over 30 days
Financial Impact
No financial impact from this filing
Risk Factors
- Insider selling could indicate lack of confidence, though this is not confirmed by this filing
- No immediate financial or strategic impact from this routine proxy statement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-027321 |
| Document: 0001628280-26-027321-index-headers.html | 0001628280-26-027321 |
| Document: 0001628280-26-027321-index.html | 0001628280-26-027321 |
| Document: 0001628280-26-027321.txt | 0001628280-26-027321 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers